{"id":"c213-microneedle-system","_chembl":{"chemblId":"CHEMBL5815900","moleculeType":null,"molecularWeight":"538.65"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"The C213 system utilizes a patch containing titanium microneedles that penetrate the stratum corneum to deliver drug formulations into the dermal microcirculation. This delivery method bypasses gastrointestinal absorption and hepatic first-pass metabolism, potentially enabling faster onset and improved bioavailability compared to oral administration.","oneSentence":"Transdermal microneedle array that delivers drug compounds through the skin for rapid systemic absorption."},"_scrapedAt":"2026-03-28T03:25:30.344Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123783,"model":"claude-sonnet-4-5-20250929"},"description":"C213 Microneedle System is a transdermal drug delivery platform developed by Zosano Pharma Corporation. The system uses an array of titanium microneedles to deliver therapeutics through the skin, enabling rapid systemic absorption while avoiding first-pass metabolism and offering an alternative to oral or injectable administration.","indications":{"approved":[{"status":"investigational","condition":"Unknown indication","patientPopulation":null}]},"trialDetails":[{"nctId":"NCT04066023","phase":"PHASE2, PHASE3","title":"Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches","status":"COMPLETED","sponsor":"Zosano Pharma Corporation","startDate":"2019-10-03","conditions":"Cluster Headache","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zolmitriptan Microneedle System"],"phase":"phase_2","status":"active","brandName":"C213 Microneedle System","genericName":"C213 Microneedle System","companyName":"Zosano Pharma Corporation","companyId":"zosano-pharma-corporation","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}